Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

9 Meters Biopharma, Inc. - Common Stock (NQ:NMTR)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 9 Meters Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
RALEIGH, NC / ACCESSWIRE / March 2, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)
RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property
News headline image
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experience RALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
RALEIGH, NC / ACCESSWIRE / January 4, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
RALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 - - Larazotide Phase 3 for celiac disease... 
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
- Collaboration builds upon previous positive preclinical data warranting further investigation of NM-102, a potential novel therapy to enhance immune checkpoint inhibitor effect - IND-enabling pathway... 
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
- In-Person Dates: November 16th-17th - Virtual Dates: November 18th-19th RALEIGH, NC / ACCESSWIRE / November 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
- Vurolenatide's half-life is consistent with twice-monthly dosing - - Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end - RALEIGH, NC / ACCESSWIRE /... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
RALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
RALEIGH, NC / ACCESSWIRE / September 27, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating... 
From 9 Meters Biopharma
Via AccessWire
Topics Hacking Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference
- Conference Dates: September 27th-30th - RALEIGH, NC / ACCESSWIRE / September 22, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Conference Dates: September 20th-23rd RALEIGH, NC / ACCESSWIRE / September 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- Conference Dates: September 13th-15th - RALEIGH, NC / ACCESSWIRE / September 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
- Conference Dates: September 08th-10th - RALEIGH, NC / ACCESSWIRE / September 1, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company focused on rare and unmet needs in... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19
-Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- -Translational evidence... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021
- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"
Conference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) - - First planned indication is Prader-Willi Syndrome- - IND-enabling... 
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Added to Russell 2000(R) and 3000(R) Indexes
RALEIGH, NC / ACCESSWIRE / June 28, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today it has... 
From 9 Meters Biopharma
Via AccessWire
Topics Derivatives Regulatory Compliance
News headline image
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.